Within a day of the July vote, the marketing started. Banner copy announcing FDA approval. Email subject lines declaring peptides legal. Landing pages describing a regulatory milestone that did not occur.
None of it was true, and the pattern is useful. A seller's description of the July meeting is one of the cleanest available tests of whether that seller understands the rules it operates under.
Here is a field guide.
What actually happened, in one paragraph
On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee voted to recommend that six of seven peptides be added to the 503A Bulk Drug Substances List: BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax. It declined to recommend emideltide (DSIP). The votes are advisory and non-binding. The FDA has not acted. No peptide was approved, and none became legal to compound. FDA's own scientists had recommended against all seven.
The claims, ranked by how wrong they are
“FDA approved” — false, and not even the right process
Drug approval requires a sponsor to demonstrate safety and efficacy through clinical trials, followed by an FDA review of that application. Nothing resembling that happened. The bulks-list question is separate: it asks whether a substance can be adequately characterized, whether it poses significant safety risks in compounded preparations, and whether enough literature exists to inform safe compounding.
A substance can be added to the bulks list without anyone having demonstrated that it works. The two processes are not adjacent.
“Now legal” — false
Section 503A permits a bulk drug substance only if it has a USP or NF monograph, is a component of an approved drug product, or appears on the 503A Bulks List. The six recommended peptides satisfy none of the three. Formal listing requires completed notice-and-comment rulemaking, which has not begun.
“Category 1 now” — false, with one exception
Removal from Category 2 does not confer Category 1 status. Of the twelve peptides delisted in April 2026, only non-injectable GHK-Cu holds Category 1 standing. The rest sit in a space with no affirmative permission attached.
“Pharmacies can compound these now” — false, and state boards are enforcing
Ohio's Board of Pharmacy has issued explicit guidance that Category 2 and Category 3 peptides cannot be compounded, and has taken enforcement action — including summary suspension in some cases — against pharmacies compounding substances including BPC-157 and CJC-1295/ipamorelin. A pharmacy telling you otherwise is describing a risk it is taking, not a permission it has.
“The FDA said these are safe” — the reverse
Agency scientists recommended against all seven nominations, citing insufficient safety data, insufficient efficacy data and inadequate characterization. The committee voted the other way. Characterizing this as an FDA safety endorsement inverts the record.
“Approved for [tendon repair / anti-aging / focus]” — false
Each peptide was evaluated for a specific indication, and those indications diverge sharply from how the compounds are marketed:
| Peptide | Indication FDA reviewed | Common marketing claim |
|---|---|---|
| BPC-157 | Ulcerative colitis | Tendon and joint repair |
| TB-500 | Wound healing | Athletic recovery |
| KPV | Wound healing, inflammatory conditions | Gut and skin health |
| MOTS-c | Obesity, osteoporosis | Metabolic optimization |
| Epitalon | Insomnia | Telomere lengthening, longevity |
| Semax | Cerebral ischemia, migraine, trigeminal neuralgia | Cognitive enhancement |
Even if a rule were finalized tomorrow, it would be written around the middle column. The right-hand column has no regulatory standing at all.
The single fastest test
If a seller says a peptide is FDA-approved or newly legal, you have learned something about the seller. Either they have not read the regulation they are describing, or they are counting on you not to. Both are disqualifying in a market where product identity and purity are the central open question.
Claims that are accurate
To be fair to sellers getting it right, these statements are true and you may reasonably see them:
- “An FDA advisory committee recommended six peptides for the 503A Bulks List in July 2026.”
- “The recommendation is non-binding and the FDA has not issued a decision.”
- “Twelve peptides were removed from Category 2 in April 2026.”
- “This product is sold for research use only and is not for human consumption.”
- “This substance is not approved by the FDA for any condition.”
Precision is not a marketing weakness in this category. It is the only real credential a vendor can offer, because everything else — purity, identity, batch consistency — is invisible to the buyer.
Why the enforcement risk is not only the FDA's
Peptide marketing sits in an unusually exposed position. Violative promotion can draw attention from the FDA, from the Federal Trade Commission, from competitors bringing false-advertising claims under the Lanham Act, and from state consumer-protection authorities. Any one of those is a functioning enforcement channel independent of whatever the 503A rulemaking eventually does.
A seller making approval claims today is not merely being loose with language. It is running a legal exposure that a buyer inherits nothing good from.
A short checklist
Six questions for any peptide seller
- Do they describe the July vote as a recommendation, or as approval?
- Do they distinguish research-use-only material from a compounded prescription?
- Do they publish per-lot third-party analytical documentation, or reference it vaguely?
- Do they make disease claims, or describe research applications?
- Do they name the actual indication reviewed, or the one people search for?
- Do they date their regulatory statements? This area is moving; undated claims go stale invisibly.
What changes, and when
Watch the Federal Register for a proposed rule. That is the first milestone with legal weight. Separately, watch for any FDA statement placing the recommended peptides in Category 1 on an interim basis or signaling enforcement discretion — that would move access considerably faster than rulemaking, and it has not happened.
Until one of those occurs, the accurate description of the current moment is short: an advisory committee made a recommendation, and nothing else has changed.
Common questions
Claims like that can create exposure under FDA authority, FTC advertising rules, the Lanham Act and state consumer-protection law. We are not offering legal advice, but as a consumer signal the claim is straightforwardly false and worth treating as disqualifying.
It names the July 2026 vote as an advisory recommendation, states that the FDA has not decided, avoids disease claims, labels research material as research-use-only, and dates its regulatory statements.
Under Section 503A, BPC-157 does not currently satisfy any of the three statutory conditions for use as a bulk drug substance. Some state boards have taken enforcement action on exactly this point. A pharmacy offering it is accepting regulatory risk, whatever it tells you.
No. Research-use-only material is a separate category that sits outside the pharmacy system entirely — no prescription, no licensed dispensing, and none of the sourcing or characterization standards a compounding rule would impose. It is not a compliant substitute for a prescription.
The FDA's advisory committee calendar carries the meeting materials and outcomes, and the Federal Register carries any proposed or final rule. Both are public and searchable. If a seller's claim cannot be traced to one of them, it is not a regulatory fact.
Sources
- US Food and Drug Administration. “July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee.” Docket FDA-2026-N-2979. fda.gov
- McDermott Will & Schulte. “Bulk-list bound? PCAC backs majority of peptides in two-day public meeting.” Client alert, July 27, 2026.
- Holland & Knight. “FDA Advisory Committee Endorses Compounding of Certain Peptides.” August 2026.
- Latham & Watkins. “FDA on Peptides: A New Landscape for Compounders.” 2026.
- Orrick. “FDA Peptide Compounding Vote: What to Watch at the July PCAC Meeting.” July 2026.
- Sheppard Mullin. “What to Watch: Status Update on Peptide Regulation.” June 2026.